Reports Q4 revenue $663,000, consensus $7.9M. CytomX ended 2025 with $137.1M of cash, cash equivalents and investments with expected cash runway to the second quarter of 2027.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CTMX:
- CytomX Therapeutics Inc. (CTMX) Q4 Earnings Cheat Sheet
- CytomX Therapeutics price target raised to $10 from $8 at Barclays
- CytomX Therapeutics participates in a conference call with Cantor
- CytomX Therapeutics initiated with a Buy at Guggenheim
- CytomX Therapeutics price target raised to $10 from $6.50 at Piper Sandler